Polacino P S, Stallard V, Klaniecki J E, Pennathur S, Montefiori D C, Langlois A J, Richardson B A, Morton W R, Benveniste R E, Hu S L
Regional Primate Research Center, University of Washington, Seattle, USA.
J Virol. 1999 Oct;73(10):8201-15. doi: 10.1128/JVI.73.10.8201-8215.1999.
We previously showed that envelope (gp160)-based vaccines, used in a live recombinant virus priming and subunit protein boosting regimen, protected macaques against intravenous and intrarectal challenges with the homologous simian immunodeficiency virus SIVmne clone E11S. However, the breadth of protection appears to be limited, since the vaccines were only partially effective against intravenous challenge by the uncloned SIVmne. To examine factors that could affect the breadth and the efficacy of this immunization approach, we studied (i) the effect of priming by recombinant vaccinia virus; (ii) the role of surface antigen gp130; and (iii) the role of core antigens (Gag and Pol) in eliciting protective immunity. Results indicate that (i) priming with recombinant vaccinia virus was more effective than subunit antigen in eliciting protective responses; (ii) while both gp130 and gp160 elicited similar levels of SIV-specific antibodies, gp130 was not as effective as gp160 in protection, indicating a possible role for the transmembrane protein in presenting functionally important epitopes; and (iii) although animals immunized with core antigens failed to generate any neutralizing antibody and were infected upon challenge, their virus load was 50- to 100-fold lower than that of the controls, suggesting the importance of cellular immunity or other core-specific immune responses in controlling acute infection. Complete protection against intravenous infection by the pathogenic uncloned SIVmne was achieved by immunization with both the envelope and the core antigens. These results indicate that immune responses to both antigens may contribute to protection and thus argue for the inclusion of multiple antigens in recombinant vaccine designs.
我们先前表明,基于包膜(gp160)的疫苗,采用重组活病毒初免和亚单位蛋白加强免疫方案,可保护猕猴免受同源猴免疫缺陷病毒SIVmne克隆E11S的静脉内和直肠内攻击。然而,保护的广度似乎有限,因为这些疫苗对未克隆的SIVmne的静脉内攻击仅部分有效。为了研究可能影响这种免疫方法的广度和效力的因素,我们研究了:(i)重组痘苗病毒初免的效果;(ii)表面抗原gp130的作用;以及(iii)核心抗原(Gag和Pol)在引发保护性免疫中的作用。结果表明:(i)重组痘苗病毒初免在引发保护性反应方面比亚单位抗原更有效;(ii)虽然gp130和gp160诱导的SIV特异性抗体水平相似,但gp130在保护方面不如gp160有效,表明跨膜蛋白在呈递功能重要表位方面可能发挥作用;以及(iii)尽管用核心抗原免疫的动物未能产生任何中和抗体且在攻击后被感染,但其病毒载量比对照组低50至100倍,这表明细胞免疫或其他核心特异性免疫反应在控制急性感染中很重要。通过用包膜抗原和核心抗原免疫,可实现对致病性未克隆SIVmne静脉内感染的完全保护。这些结果表明,对两种抗原的免疫反应可能有助于提供保护,因此支持在重组疫苗设计中纳入多种抗原。